Demographics and baseline characteristics
| Pramipexole | Placebo | Total | |
|---|---|---|---|
| Number of patients | 341-150 | 44 | 781-150 |
| Sex: | |||
| Men | 20 (58.8%) | 31 (70.5%) | 51 (65.4%) |
| Women | 14 (41.2%) | 13 (29.5%) | 27 (34.6%) |
| Age (y) | 59.3 (8.3) | 60.7 (8.7) | 60.1 (8.5) |
| Duration (y) of Parkinson’s disease | 7.8 (4.3) | 8.5 (5.2) | 8.2 (4.8) |
| Hoehn and Yahr stage: | |||
| II | 7 (20.6%) | 13 (29.5%) | 20 (25.6%) |
| III | 22 (64.7%) | 20 (45.5%) | 42 (35.9%) |
| IV | 5 (14.7%) | 11 (25.0%) | 16 (20.5%) |
| UPDRS total score | 53.6 (14.0) | 50.2 (20.0) | 51.7 (17.6) |
| UPDRS part I | 1.5 (1.8) | 1.1 (1.5) | 1.2 (1.6) |
| UPDRS part II | 13.0 (4.9) | 12.7 (7.3) | 12.8 (6.3) |
| UPDRS part III | 33.5 (9.1) | 30.5 (12.2) | 31.8 (11.0) |
| UPDRS part IV | 5.7 (4.0) | 5.9 (3.5) | 5.8 (3.7) |
| Antiparkinson medication: | |||
| Only levodopa | |||
| ⩽600mg | 5 (14.7%) | 7 (15.9%) | 12 (15.4%) |
| >600mg | 4 (11.8%) | 8 (18.2%) | 12 (15.4%) |
| Levodopa and other | |||
| ⩽600mg | 15 (44.2%) | 16 (36.4%) | 31 (39.7%) |
| >600mg | 10 (29.4%) | 13 (29.6%) | 23 (29.5%) |
↵1-150 One patient was randomised to both treatment groups. Values are mean (SD) or mean (%).